文献速递创伤与烧伤

暴力再损伤轨迹跨损伤机制:一项多中心队列研究

Violent Reinjury Trajectories Across Injury Mechanisms: A Multicenter Cohort Study
RSS 订阅 · Annals of Emergency Medicine · 2026-11-09
一句话结论暴力损伤幸存者再损伤风险与男性、黑人及其他种族、成人医院就诊、公共保险、高社会脆弱性相关;<18岁火器伤者火器再伤风险高于18-26岁(aHR 0.65)。

本研究为观察性队列研究,纳入2016至2023年2家成人及2家儿科一级创伤中心共29,038例非致命性暴力损伤(钝性袭击、刺伤、火器伤)患者,采用多因素Cox比例风险模型分析各协变量与再损伤时间的关联。结果显示男性、黑人及其他种族、成人医院就诊、公共保险、居住于高社会脆弱性地区与任何暴力再损伤风险升高相关。火器伤患者中,<18岁者火器再伤风险高于18-26岁(aHR 0.65)和>26岁者(aHR 0.47);女性火器伤者火器再伤风险低于男性(aHR 0.46),但钝性再伤风险更高(aHR 1.77)。高社会脆弱性地区患者升级性再损伤机制(如钝性转为火器)风险高于低/平均社会脆弱性地区(aHR 1.46)。作者认为应加强关键亚组的再损伤预防。

要点

  • 29,038例非致命暴力损伤中,男性(66.4%)、黑人及其他种族(73.7%)、成人医院就诊(83.3%)、公共保险(47.8%)、高社会脆弱性地区(72.5%)与任何暴力再损伤风险升高相关。
  • 火器伤患者中,<18岁者火器再伤风险高于18-26岁者(aHR 0.65 [0.47-0.91])和>26岁者(aHR 0.47 [0.34-0.66])。
  • 女性火器伤者火器再伤风险低于男性(aHR 0.46 [0.36-0.58]),但钝性再伤风险更高(aHR 1.77 [1.34-1.24];原文置信区间上限1.24低于点估计1.77,原文此处数值表述有矛盾)。
  • 高社会脆弱性地区患者升级性再损伤机制(如钝性转为火器)风险高于低/平均社会脆弱性地区(aHR 1.46 [1.11-1.90])。
  • 作者认为应针对关键亚组加强再损伤预防。

适用人群与场景

  • 2016至2023年2家成人及2家儿科一级创伤中心收治的非致命性暴力损伤患者(钝性袭击、刺伤、火器伤)。

研究设计与关键结果

  • 研究类型:观察性队列研究;样本量29,038例非致命性暴力损伤;2家成人及2家儿科一级创伤中心;2016至2023年。
  • 主要结局为再损伤时间,采用多因素Cox比例风险模型分析各协变量与再损伤时间的关联。
  • 男性(n=19,273;66.4%)、黑人及其他种族(n=21,403;73.7%)、成人医院就诊(n=24,200;83.3%)、公共保险(n=13,879;47.8%)、高社会脆弱性地区(n=21,044;72.5%)与任何暴力再损伤风险升高相关(校正协变量后)。
  • 火器伤患者中,<18岁者火器再伤风险高于18-26岁者(aHR 0.65 [0.47-0.91])和>26岁者(aHR 0.47 [0.34-0.66])。
  • 女性火器伤者火器再伤风险低于男性(aHR 0.46 [0.36-0.58]),但钝性再伤风险更高(aHR 1.77 [1.34-1.24];原文置信区间上限1.24低于点估计1.77,原文此处数值表述有矛盾)。
  • 高社会脆弱性地区患者升级性再损伤机制(如钝性转为火器)风险高于低/平均社会脆弱性地区(aHR 1.46 [1.11-1.90])。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究结果凸显了暴力再损伤后果受特定人口学和临床特征影响,为在关键亚组中加强再损伤预防提供了机会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Survivors of violent injury often experience reinjury. We sought to identify demographic and clinical factors associated with violent reinjury across different injury types.

METHODS: We conducted an observational cohort study of individuals with violent injury (ie, blunt assaults, stabbings, and firearm injuries) across 2 adult and 2 pediatric Level I trauma centers from 2016 to 2023. Covariates included age, sex, race, hospital type, insurance status, and social vulnerability. Our primary outcome was time to reinjury. We used multivariable Cox proportional hazards models to measure associations between each covariate and time to reinjury across injury types.

RESULTS: There were 29,038 individuals with nonfatal violent injuries. Male sex (n=19,273; 66.4%), Black and other race (n=21,403; 73.7%), presentation to adult hospitals (n=24,200; 83.3%), public insurance (n=13,879; 47.8%), and living in an area with high social vulnerability (n=21,044; 72.5%) were associated with a greater risk of any violent reinjury, adjusting for covariates. For index firearm injuries, patients younger than18 years had greater risk of firearm reinjury than patients aged 18 to 26 years (adjusted hazard ratio [aHR]:0.65 [0.47 to 0.91]) and for those older than 26 years (aHR:0.47 [0.34 to 0.66]). Although women with firearm injury had a lower risk of firearm reinjury compared with men (aHR:0.46 [0.36 to 0.58]), they had greater risk of blunt reinjury (aHR:1.77 [1.34 to 1.24]). Patients living in areas with high social vulnerability had a higher risk of escalating reinjury mechanism (eg, blunt to firearm; aHR:1.46 [1.11 to 1.90]) versus patients in areas with low/average social vulnerability.

CONCLUSION: This research underscores how sequelae of violent reinjury are shaped by certain demographic and clinical characteristics, highlighting opportunities to strengthen reinjury prevention in key subgroups.

来源:Annals of Emergency Medicine,查看原文。版权归原作者所有。

参考来源

  1. Annals of Emergency Medicine:Violent Reinjury Trajectories Across Injury Mechanisms: A Multicenter Cohort Study
  2. Szoko N, Lew D, Kaser T, et al. Violent Reinjury Trajectories Across Injury Mechanisms: A Multicenter Cohort Study. Ann Emerg Med. 2026. PMID: 43007248. doi:10.1016/j.annemergmed.2026.09.024

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。